MX2021013310A - Preparaciones de factor de cogulación para la administración en el tejido del tracto intestinal usando un dispositivo de administración de medicamentos ingeribles. - Google Patents
Preparaciones de factor de cogulación para la administración en el tejido del tracto intestinal usando un dispositivo de administración de medicamentos ingeribles.Info
- Publication number
- MX2021013310A MX2021013310A MX2021013310A MX2021013310A MX2021013310A MX 2021013310 A MX2021013310 A MX 2021013310A MX 2021013310 A MX2021013310 A MX 2021013310A MX 2021013310 A MX2021013310 A MX 2021013310A MX 2021013310 A MX2021013310 A MX 2021013310A
- Authority
- MX
- Mexico
- Prior art keywords
- capsule
- cfs
- preparation
- delivery
- preparations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3295—Multiple needle devices, e.g. a plurality of needles arranged coaxially or in parallel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
- A61M2005/14284—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation with needle insertion means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3507—Communication with implanted devices, e.g. external control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6063—Optical identification systems
- A61M2205/6072—Bar codes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Las modalidades proporcionan dispositivos, preparaciones y métodos para administrar agentes terapéuticos (TA) tales como factores de coagulación (CF), por ejemplo, Factor VIII (FVIII) que incluye PEGilado y otras formas de FVIII estabilizado, dentro del tracto GI. Muchas modalidades proporcionan un dispositivo ingerible, por ejemplo, una cápsula para administrar TA en la pared intestinal (IW). Las modalidades también proporcionan preparaciones de TA configuradas para estar contenidas dentro de la cápsula, avanzar desde la cápsula a la IW y/o tejido circundante (ST) y degradarse para liberar TA en el torrente sanguíneo para producir un efecto terapéutico (por ejemplo, coagulación mejorada). La preparación puede acoplarse operativamente a un medio de administración que tiene una primera configuración donde la preparación está contenida en la cápsula y una segunda configuración en donde la preparación avanza fuera de la cápsula a la IW o ST (por ejemplo, la cavidad peritoneal). Las modalidades son particularmente útiles para la administración de CF para el tratamiento de trastornos de la coagulación (por ejemplo, hemofilia) donde tales CF se absorben mal y/o se degradan dentro del tracto GI.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962843221P | 2019-05-03 | 2019-05-03 | |
US201962845209P | 2019-05-08 | 2019-05-08 | |
PCT/US2020/031197 WO2020227162A1 (en) | 2019-05-03 | 2020-05-01 | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021013310A true MX2021013310A (es) | 2022-02-11 |
Family
ID=73050863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021013310A MX2021013310A (es) | 2019-05-03 | 2020-05-01 | Preparaciones de factor de cogulación para la administración en el tejido del tracto intestinal usando un dispositivo de administración de medicamentos ingeribles. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220118056A1 (es) |
EP (1) | EP3962516A4 (es) |
JP (1) | JP2022530615A (es) |
KR (1) | KR20220004148A (es) |
CN (1) | CN114007638A (es) |
AU (1) | AU2020270420A1 (es) |
BR (1) | BR112021021904A2 (es) |
CA (1) | CA3137539A1 (es) |
MX (1) | MX2021013310A (es) |
WO (1) | WO2020227162A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
AU2018366110A1 (en) | 2017-11-07 | 2020-06-04 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
MX2023009810A (es) * | 2021-02-24 | 2023-08-30 | Rani Therapeutics Llc | Tratamientos para la hemofilia a. |
AU2022258553A1 (en) * | 2021-04-13 | 2023-11-02 | Grifols Worldwide Operations Limited | Liquid composition comprising factor viii or factor viii/von willebrand factor complex |
CN115300774B (zh) * | 2022-08-27 | 2024-01-30 | 深圳市资福医疗技术有限公司 | 一种药剂递送装置、释药方法及应用其的释药胶囊 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9149617B2 (en) * | 2010-12-23 | 2015-10-06 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
LT3513804T (lt) * | 2011-07-08 | 2022-05-25 | Bioverativ Therapeutics Inc. | Viii faktorius chimeriniai ir hibridiniai polipetidai bei jų panaudojimo būdai |
US20140019297A1 (en) * | 2012-07-10 | 2014-01-16 | Bootic, Inc. | Electronic Commerce System Incorporating Shopping Baskets |
US10689460B2 (en) * | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US11548940B2 (en) * | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
JP7202070B2 (ja) * | 2015-05-01 | 2023-01-11 | ラニ セラピューティクス, エルエルシー | ポリペプチドおよび/またはタンパク質を含む固体塊の製作のための薬学的組成物および方法 |
AU2016320867B2 (en) * | 2015-09-08 | 2023-03-30 | Rani Therapeutics, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
JP6877469B2 (ja) * | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチMogam Institute For Biomedical Research | Fviiiおよびvwf因子を含むキメラタンパク質、ならびにそれらの使用 |
AU2018366110A1 (en) * | 2017-11-07 | 2020-06-04 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
-
2020
- 2020-05-01 JP JP2021562389A patent/JP2022530615A/ja active Pending
- 2020-05-01 AU AU2020270420A patent/AU2020270420A1/en active Pending
- 2020-05-01 WO PCT/US2020/031197 patent/WO2020227162A1/en unknown
- 2020-05-01 CN CN202080047333.3A patent/CN114007638A/zh active Pending
- 2020-05-01 MX MX2021013310A patent/MX2021013310A/es unknown
- 2020-05-01 KR KR1020217038935A patent/KR20220004148A/ko unknown
- 2020-05-01 BR BR112021021904A patent/BR112021021904A2/pt unknown
- 2020-05-01 EP EP20801591.7A patent/EP3962516A4/en active Pending
- 2020-05-01 CA CA3137539A patent/CA3137539A1/en active Pending
-
2021
- 2021-10-29 US US17/515,284 patent/US20220118056A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220118056A1 (en) | 2022-04-21 |
AU2020270420A1 (en) | 2021-11-18 |
CN114007638A (zh) | 2022-02-01 |
EP3962516A4 (en) | 2023-01-04 |
BR112021021904A2 (pt) | 2022-02-22 |
KR20220004148A (ko) | 2022-01-11 |
WO2020227162A1 (en) | 2020-11-12 |
JP2022530615A (ja) | 2022-06-30 |
CA3137539A1 (en) | 2020-10-20 |
EP3962516A1 (en) | 2022-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021013310A (es) | Preparaciones de factor de cogulación para la administración en el tejido del tracto intestinal usando un dispositivo de administración de medicamentos ingeribles. | |
MX2021011047A (es) | Preparaciones de agentes terapéuticos y métodos para la administración de fármacos en un lumen del tracto intestinal usando un dispositivo de administración de fármacos ingerible. | |
MX2021007904A (es) | Preparaciones de agente terapéutico para administración en un lumen del tracto intestinal utilizando un dispositivo de administración de fármaco tragable. | |
WO2011112229A3 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
BR0008039A (pt) | Combinações de formoterol e um sal de tiotrópio | |
JP2015524444A5 (es) | ||
KR101900520B1 (ko) | 복합 조성물 | |
UA102885C2 (ru) | Таблетка для орального введения, которая содержит тамсулозин и солифенацин | |
RU2017121203A (ru) | НОВЫЕ ПОЛИМЕРНЫЕ hGH ПРОЛЕКАРСТВА | |
MY190257A (en) | Optimised subcutaneous therapeutic agents | |
JP5684954B1 (ja) | 安定性を改善したロクロニウム製剤 | |
MX2008013635A (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. | |
WO2007081486A3 (en) | Oral administration of defensins to treat intestinal diseases | |
WO2001062799A3 (en) | Method for inhibiting angiogenesis using molecules that enhance plasmin activity | |
WO2009003694A3 (en) | Method for treating diseases related to mitochondrial dysfunction | |
MY166524A (en) | Therapeutic substance, pharmaceutical composition, helicobacter pylori growth inhibitor and method for conducting anti-helicobacter therapy | |
US20240123168A1 (en) | Product delivery devices and methods | |
IS8373A (is) | Notkun oxkarbasepíns til að meðhöndla sársauka vegna sykursýkisfjöltauga-kvilla og til að bæta svefn | |
RU2010140888A (ru) | Улучшенные противораковые терапии | |
JP4903694B2 (ja) | 抗血管形成作用を有する医薬の製造のためのトリフルオロ酢酸カルシウムの使用 | |
JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
EP2559432A1 (en) | Means for the prophylaxis and treatment of acute and chronic pancreatitis | |
AR062894A1 (es) | Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths) | |
MX2019008076A (es) | Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. | |
WO2008079818A3 (en) | Intravenous administration of water soluble analgesic formulations |